Cargando…

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

BACKGROUND: With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals. Sodium-glucose co-transporter-2 (SGLT2) inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hropot, Tim, Battelino, Tadej, Dovc, Klemen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652647/ https://www.ncbi.nlm.nih.gov/pubmed/36279850 http://dx.doi.org/10.1159/000527653

Ejemplares similares

Time in range centered diabetes care
por: Dovc, Klemen, et al.
Publicado: (2021)

Patient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin delivery
por: Gianini, Ana, et al.
Publicado: (2022)

Contribution of Retrotransposons to the Pathogenesis of Type 1 Diabetes and Challenges in Analysis Methods
por: Štangar, Anja, et al.
Publicado: (2023)

Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial
por: Dovc, Klemen, et al.
Publicado: (2017)

Acute Hyperglycemia and Spatial Working Memory in Adolescents With Type 1 Diabetes
por: Šuput Omladič, Jasna, et al.
Publicado: (2020)

Screening of lipids and kidney function in children and adolescents with Type 1 Diabetes: does age matter?
por: Catamo, Eulalia, et al.
Publicado: (2023)

Carer's Attachment Anxiety, Stressful Life-Events and the Risk of Childhood-Onset Type 1 Diabetes
por: Turin, Anja, et al.
Publicado: (2021)

Altered Taste Function in Young Individuals With Type 1 Diabetes
por: Catamo, Eulalia, et al.
Publicado: (2022)

Role of HNFA1 Gene Variants in Pancreatic Beta Cells Function and Glycaemic Control in Young Individuals with Type 1 Diabetes
por: Robino, Antonietta, et al.
Publicado: (2023)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes
por: Tesovnik, Tine, et al.
Publicado: (2020)

Validation of the Lifetime Incidence of Traumatic Events (LITE-S/P) Questionnaires in Children and Adolescents in Slovenia
por: Uršič, Katarina, et al.
Publicado: (2021)

Editorial: Daily challenges around physical exercise, nutrition and medication in type 1 diabetes
por: Moser, Othmar, et al.
Publicado: (2023)

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
por: Fatima, Tehreem, et al.
Publicado: (2020)

Attachment in close relationships and glycemic outcomes in children with type 1 diabetes
por: Klemenčič, Simona, et al.
Publicado: (2023)

Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
por: Battelino, Tadej, et al.
Publicado: (2021)

Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
por: Battelino, Tadej, et al.
Publicado: (2011)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
por: Seo, Ji A
Publicado: (2018)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Kumar, Surender, et al.
Publicado: (2019)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

Sodium‐glucose co‐transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials
por: Boeder, Schafer, et al.
Publicado: (2019)

Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
por: Torimoto, Keiichi, et al.
Publicado: (2017)

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
por: Brunton, S. A.
Publicado: (2015)

Benefits/Risks of Sodium–Glucose Co-Transporter 2 Inhibitor Canagliflozin in Women for the Treatment of Type 2 Diabetes
por: Kushner, Pamela
Publicado: (2016)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors
por: Niazi, Asfandyar Khan, et al.
Publicado: (2010)

Euglycemic diabetic ketoacidosis by sodium glucose co-transporter inhibitors: Real but preventable concern
por: Raut, Monish S, et al.
Publicado: (2017)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes
por: Sharma, M D
Publicado: (2015)

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Storgaard, Heidi, et al.
Publicado: (2016)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK
por: Evans, Marc, et al.
Publicado: (2017)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?
por: Giorgino, Francesco, et al.
Publicado: (2020)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
por: Dekkers, Claire C. J., et al.
Publicado: (2019)

Risk of lower extremity amputations in patients with type 2 diabetes using sodium-glucose co-transporter 2 inhibitors
por: Zerovnik, Spela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cb4kvj8b7sbmb357ohemqr2loc